drugset / Trial / NCT04242238
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
RandomizedSequentialOpen-labelTreatment
Summary
This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.
Timeline
- Start
- 2020-01-22
- Primary completion
- 2025-08-26
- Completion
- 2025-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Vimseltinib | Small molecule | — | Oral |